Uproleselan for Acute Myeloid Leukemia

Phase-Based Progress Estimates
University of California Davis Comprehensive Cancer Center, Sacramento, CAAcute Myeloid LeukemiaUproleselan - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a combination of drugs to treat leukemia in patients who are older or unable to have standard treatment.

Eligible Conditions
  • Acute Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 8 Secondary · Reporting Duration: Up to 3 years

Year 3
Relapse-free survival (RFS)
Year 3
Duration of CR/CRi and CR/CRh (DoR)
Year 3
Overall survival (OS)
Year 3
Event-free survival (EFS)
Up to 3 years
Overall response rate (ORR)
Rate of CR plus CR with partial count recovery (CRh)
Rate of multiparameter flow cytometry (MFC) measurable/minimal residual disease (MRD) negative complete remission (CR) plus CR with incomplete count recovery (CRi)
Rate of transfusion-independence (TI)
Up to 30 days
Incidence of adverse events
Day 28
Recommended phase II dose

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treatment (uproleselan, azacitidine, venetoclax)
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Uproleselan · No Placebo Group · Phase 1

Treatment (uproleselan, azacitidine, venetoclax)Experimental Group · 3 Interventions: Venetoclax, Azacitidine, Uproleselan · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Brian JonasLead Sponsor
4 Previous Clinical Trials
65 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,162,283 Total Patients Enrolled
GlycoMimetics IncorporatedIndustry Sponsor
22 Previous Clinical Trials
1,496 Total Patients Enrolled
Brian A JonasPrincipal InvestigatorUniversity of California, Davis
3 Previous Clinical Trials
68 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not yet received treatment for your condition and are able to receive a combination of venetoclax and hypomethylating agents.

Frequently Asked Questions

Is there a documented history of research into the therapeutic effects of Uproleselan?

"Currently, there are 345 ongoing trials for Uproleselan with 56 studies in the third phase. Although several of these tests occur out of Edmonton, Alberta; a total of 11265 locations around the globe are running clinical trials involving Uproleselan." - Anonymous Online Contributor

Unverified Answer

What is the main focus of this investigation?

"According to the research sponsor, GlycoMimetics Incorporated, this trial will be measuring a Recommended Phase II Dose as its primary outcome over an interval of up to thirty days. The secondary outcomes include Duration of CR/CRi and CR/CRh (DoR), Rate of Transfusion-Independence (TI) and Rate of Multiparameter Flow Cytometry (MFC) Measurable/Minimal Residual Disease (MRD)-Negative Complete Remission plus CR with Incomplete Count Recovery. Descriptive statistics such as means, medians and percentiles alongside Exact 95%" - Anonymous Online Contributor

Unverified Answer

What conditions tend to be treated with Uproleselan?

"Uproleselan is generally used in induction chemotherapy, but can also prove effective for refractory anemias, various forms of leukemia and dysplasias involving multiple lineages." - Anonymous Online Contributor

Unverified Answer

Are there still opportunities to enroll in this experiment?

"Clinicaltrials.gov shows that this clinical experiment is currently recruiting participants. It was initially uploaded on July 2nd 2021 and was recently revised on August 12th 2022." - Anonymous Online Contributor

Unverified Answer

What evidence is there to support the safety of Uproleselan when administered to humans?

"There is limited evidence surrounding its safety and efficacy, so Uproleselan received a rating of 1." - Anonymous Online Contributor

Unverified Answer

How many participants are allowed to join this research endeavor?

"Affirmative. Clinicaltrials.gov documentation indicates that this experiment, which was introduced on July 2nd 2021, is actively recruiting subjects. Approximately 25 people need to be enrolled from 1 medical facility." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.